ketorolac has been researched along with Carcinoma, Epidermoid in 4 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketorolac salt was selected based on its binding free energy less than or equals to -5 Kcal/mol with reference to existing synthetic DDX3 inhibitors and strong hydrogen bond interactions as similar to crystallized DDX3 protein (2I4I)." | 1.42 | Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer. ( Botlagunta, M; Dash, R; Routray, S; Samal, SK; Veeramachaneni, GK, 2015) |
| "The intraoperative use of NSAIDs in breast cancer patients (Centre 1) is associated with a reduced recurrence rate (HR = 0." | 1.39 | Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. ( Berliere, M; Canon, JL; Coulie, PG; De Kock, M; Forget, P; Kremer, Y; Legrand, C; Machiels, JP; Poncelet, AJ; Stainier, A; Tombal, B, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forget, P | 1 |
| Machiels, JP | 1 |
| Coulie, PG | 1 |
| Berliere, M | 1 |
| Poncelet, AJ | 1 |
| Tombal, B | 1 |
| Stainier, A | 1 |
| Legrand, C | 1 |
| Canon, JL | 1 |
| Kremer, Y | 1 |
| De Kock, M | 1 |
| Samal, SK | 1 |
| Routray, S | 1 |
| Veeramachaneni, GK | 1 |
| Dash, R | 1 |
| Botlagunta, M | 1 |
| McCann, KJ | 1 |
| Irish, J | 1 |
| Blackwell, N | 1 |
| Bangham, L | 1 |
| Hughes, M | 1 |
| Melzack, D | 1 |
| Trotman, I | 1 |
4 other studies available for ketorolac and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Carcinoma, Non-Small-Cell | 2013 |
Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; DEAD-box | 2015 |
Postoperative gastrointestinal bleeding: a case report involving a non-steroidal anti-inflammatory drug.
Topics: Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Female; Histami | 1994 |
Treatment of resistant pain in hypertrophic pulmonary arthropathy with ketorolac.
Topics: Administration, Cutaneous; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; | 1993 |